美国外周动脉疾病患者预防与生活方式咨询不足
研究基于2005至2012年美国门诊调查中1,982次外周动脉疾病(PAD)患者就诊数据,评估药物治疗与生活方式咨询趋势。结果显示抗血小板、他汀、ACEI/ARB及西洛他唑使用率低,运动/饮食咨询和戒烟干预不足,且8年间无显著改善;合并冠心病者用药与戒烟咨询几率更高。
要点
- PAD患者抗血小板治疗仅35.7%,他汀33.1%,ACEI/ARB 28.4%,西洛他唑4.7%。
- 运动或饮食咨询仅22%,当前吸烟者戒烟咨询或药物仅35.8%。
- 2005至2012年药物治疗与生活方式咨询无显著变化。
核心结论
- PAD患者指南推荐治疗的使用远低于预期,凸显改善这组高危患者照护质量的机会。
研究设计与样本
- 研究采用美国国家门诊医疗调查与国家医院门诊医疗调查2005至2012年数据,纳入1,982次PAD患者门诊就诊,为全国代表性评估。
主要发现
- 8年间美国PAD年均门诊量3,883,665次,平均年龄69.2岁,女性51.8%,非西班牙裔白人56.6%,合并冠心病24.3%。
- 抗血小板治疗35.7%(SE 2.7%),他汀33.1%(SE 2.4%),ACEI/ARB 28.4%(SE 2.0%),西洛他唑4.7%(SE 1.0%)。
- 运动或饮食咨询22%(SE 2.3%);当前吸烟PAD患者中戒烟咨询或药物35.8%(SE 4.6%)。
- 药物治疗与生活方式咨询随时间无显著变化。
- 与单纯PAD就诊相比,合并PAD和CAD者更可能处方抗血小板(OR 2.6;95%CI 1.8-3.9)、他汀(OR 2.6;95%CI 1.8-3.9)、ACEI/ARB(OR 2.6;95%CI 1.8-3.9)及接受戒烟咨询(OR 4.4;95%CI 2.0-9.6)。
临床怎么用
- 研究提示PAD患者中指南推荐药物与生活方式咨询使用不足,合并冠心病者接受部分干预的几率更高。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about patterns of medication use and lifestyle counseling in patients with peripheral artery disease (PAD) in the United States. OBJECTIVES: The authors sought to evaluate trends in both medical therapy and lifestyle counseling for PAD patients in the United States from 2005 through 2012. METHODS: Data from 1,982 outpatient visits among patients with PAD were obtained from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, a nationally representative assessment of office-based and hospital outpatient department practice. Trends in the proportion of visits with medication use (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) and lifestyle counseling (exercise or diet counseling and smoking cessation) were evaluated. RESULTS: Over the 8-year period, the average annual number of ambulatory visits in the United States for PAD was 3,883,665. Across all visits, mean age was 69.2 years, 51.8% were female, and 56.6% were non-Hispanic white. Comorbid coronary artery disease (CAD) was present in 24.3% of visits. Medication use for cardiovascular prevention and symptoms of claudication was low: any antiplatelet therapy in 35.7% (standard error [SE]: 2.7%), statin in 33.1% (SE: 2.4%), ACEI/ARB in 28.4% (SE: 2.0%), and cilostazol in 4.7% (SE: 1.0%) of visits. Exercise or diet counseling was used in 22% (SE: 2.3%) of visits. Among current smokers with PAD, smoking cessation counseling or medication was used in 35.8% (SE: 4.6%) of visits. There was no significant change in medication use or lifestyle counseling over time. Compared with visits for patients with PAD alone, comorbid PAD and CAD were more likely to be prescribed antiplatelet therapy (odds ratio [OR]: 2.6; 95% confidence interval [CI]: 1.8 to 3.9), statins (OR: 2.6; 95% CI: 1.8 to 3.9), ACEI/ARB (OR: 2.6; 95% CI: 1.8 to 3.9), and smoking cessation counseling (OR: 4.4; 95% CI: 2.0 to 9.6). CONCLUSIONS: The use of guideline-recommended therapies in patients with PAD was much lower than expected, which highlights an opportunity to improve the quality of care in these high-risk patients.
引用
- Berger JS, Ladapo JA. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2017. PMID: 28473134. doi:10.1016/j.jacc.2017.02.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。